John Mugwanya Mulo
ID: UNCST-2026-R023496
|
Digital Media and Malaria Vaccine: Perceptions of Parents with Children Under Five in Wakiso and Karenga Districts, in Uganda
REFNo: SS5060ES
In general, the research will understand the perceptions of parents with children under five years of age on the influence of digital media on the uptake of the malaria vaccine in Wakiso and Karenga Districts. Specifically, it will: explore how parents of children under five in Wakiso and Karenga Districts in Uganda perceive the influence of digital media on malaria vaccine acceptance, identify barriers and facilitators to malaria vaccine uptake shaped by digital media exposure and develop qualitative insights and recommendations for leveraging trusted digital media channels to enhance malaria vaccine uptake, complementing interventions like vector control, case management, chemoprevention and surveillance.
|
Uganda |
2026-04-10 18:17:56 |
2029-04-10 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
William Worodria Ofuti
ID: UNCST-2022-R010915
|
Program for Rifampicin-Resistant Disease with Stratified Medicine for TB” (PRISM-TB)
REFNo: HS7398ES
To identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.
1. To evaluate whether a BPaLM strategy of 17 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
2. To evaluate whether a BPaLM strategy of 17 weeks for all participants has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
3. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
4. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 17 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
5. To compare the proportion of participants who experience grade 3 or higher adverse events by Week 28 in the preferred BPaLM strategy to the control strategy.
6. To compare the proportion of participants who experience adverse events of special interest by Week 28 in the preferred BPaLM strategy to the control strategy.
7. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive shorter treatment.
8. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive longer treatment.
9. To evaluate the pharmacokinetics of all drugs in the BPaLM regimen with an additional focus on bedaquiline elimination (Stages 1 and 2).
10. To determine the dose-response and exposure-response relationships between study drug estimated PK parameters with efficacy and toxicity (Stages 1 and 2).
11. To evaluate the feasibility and acceptability of treatment stratification in the context of treatment for MDR/RR-TB from the participant and the health system perspective (Stages 1 and 2).
|
Uganda |
2026-04-10 18:15:27 |
2029-04-10 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Kimuli NamyaloAngella
ID: UNCST-2025-R022072
|
PREVALENCE OF HELICOBACTER PYLORI, ASSOCIATED FACTORS AND MAGNITUDE OF RESISTANCE AGAINST FIRST LINE ANTIBIOTICS AMONG CHILDREN PRESENTING WITH GASTRO-INTESTINAL SYMPTOMS AT HOLY INNOCENTS CHILDREN’S HOSPITAL, SOUTHWESTERN UGANDA
REFNo: HS6980ES
1. To determine the prevalence of H. pylori infection among children aged 1-16 years at Holy Innocents Children’s Hospital, southwestern Uganda
2. To assess the factors associated with the presence of H. pylori among children presenting with gastrointestinal symptoms at Holy Innocents Children’s Hospital, Southwestern Uganda
3. To determine the proportion of H. pylori strains that possess resistance genes to Amoxicillin, metronidazole and clarithromycin among the children population at Holy Innocents Children’s Hospital, Southwestern Uganda
|
Uganda |
2026-04-10 18:12:39 |
2029-04-10 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
ASIPHAS OWARAGANISE
ID: UNCST-2026-R023544
|
Licensing Foreign Trained Doctors and Dentists in Uganda: Performance and Stakeholder Perspectives, 2015-2025.
REFNo: HS7299ES
Our overarching goal is to generate robust, mixed-methods evidence detailing trends, grades, and the perspectives of FTDs and their examiners to inform the professional council’s policies on licensure and workforce integration. Specifically, we will i) characterize the structural attributes and outcome performance of FTDs seeking licensure in Uganda, and ii) explore stakeholder experiences and perceptions of the medical licensure process for FTDs, situating findings within the context of evolving regional health workforce policies
|
Uganda |
2026-04-10 18:11:34 |
2029-04-10 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Sally Hargreaves
ID: UNCST-2025-R022294
|
Designing for Immunization: A Co-design Thinking Approach to
Improving Catch-up Vaccination among South Sudanese Refugees in Uganda (TUKU-VAC Study)
REFNo: HS7289ES
This project aims to explore the drivers of catch-up vaccination uptake among South Sudanese refugees in Uganda and to co-design community-led solutions using a participatory, design thinking research approach. Refugees often face significant challenges in accessing vaccinations, including limited healthcare access, vaccine hesitancy, misinformation, and systemic barriers. This study seeks to gain a deeper understanding of these issues and develop culturally appropriate, sustainable strategies to improve uptake of essential catch-up vaccines. The study will utilise an adapted version of the World Health Organization’s Behavioural and Social Drivers (BeSD) of vaccination framework to examine the key social behavioural factors influencing vaccine uptake among migrants and refugees’ population. This framework considers four key domains: individuals’ cognitive and emotional responses to vaccine-preventable diseases and vaccines, the influence of social norms and recommendations, the level of motivation and willingness to be vaccinated, and the practical barriers individuals encounter when attempting to access vaccination services. In parallel, a complementary healthcare provider survey adapted from a CDC-developed knowledge, attitudes, and practices (KAP) survey on catch-up vaccination, previously implemented in a national study in the United States will be used to assess the knowledge, practices, and system-level barriers affecting the delivery of catch-up vaccination services to refugees. This tool covers four core domains: demographic and professional characteristics; knowledge and awareness of catch-up vaccination; service delivery practices; and perceived enablers and barriers to vaccine provision. The research will be conducted in collaboration with refugee communities and healthcare providers to ensure that interventions are locally relevant, practical, and effective. Through qualitative interviews and participatory co-design workshops, refugees and healthcare providers will collectively identify challenges and develop solutions that align with their needs and lived experiences.
|
UK |
2026-04-10 18:09:36 |
2029-04-10 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|